Cancer Treatment Reviews
Papers 2944
1 page of 295 pages (2,944 results)
#1Liza G.G. van Lent Ma (EUR: Erasmus University Rotterdam)
#1Liza G. G. van Lent (EUR: Erasmus University Rotterdam)H-Index: 2
Last. Maja J.A. de Jonge (EUR: Erasmus University Rotterdam)H-Index: 35
view all 8 authors...
Abstract Background For many patients with advanced cancer, the decision whether to participate in early phase clinical trials or not is complex. The decision-making process requires an in-depth discussion of patient values. We therefore aimed to synthesize and describe patient values that may affect early phase clinical trial participation. Methods We conducted a systematic search in seven electronic databases on patient values in relation to patients’ decisions to participate in early phase cl...
#1Federica Giugliano (IEO: European Institute of Oncology)H-Index: 2
#2Edoardo Crimini (IEO: European Institute of Oncology)H-Index: 1
Last. Paolo A. AsciertoH-Index: 91
view all 0 authors...
Abstract null null In the last decade, immunotherapy and target therapy have revolutionized the prognosis of patients with BRAF-V600 mutation-positive metastatic melanoma. To date, three different combinations of BRAF/MEK inhibitors have been approved for this population, showing comparable efficacy and unique toxicity profiles. Several immune-checkpoint inhibitors, including pembrolizumab, nivolumab and the combination of nivolumab plus ipilimumab, are also available options for untreated metas...
#1Kaushal Parikh (Hackensack University Medical Center)H-Index: 7
#2Lizza E.L. Hendriks (Maastricht University Medical Centre)H-Index: 21
Last. Jordi RemonH-Index: 27
view all 0 authors...
Malignant pleural mesothelioma (MPM) is a rare and orphan thoracic malignancy, with a poor prognosis as the majority of patients are diagnosed with unresectable MPM, with no significant improvements in the therapeutic strategy for over a decade. However, the recent approval of immune checkpoint inhibitors (ICI) in treatment-naive patients with unresectable MPM marks a significant step forward and hope for the treatment of this disease. In this narrative review, we discuss the biological rational...
#1Charlotte I. Stroes (UvA: University of Amsterdam)H-Index: 4
#2Tom van den Ende (UvA: University of Amsterdam)H-Index: 8
Last. Hanneke W. M. van Laarhoven (UvA: University of Amsterdam)H-Index: 40
view all 0 authors...
Introduction null Despite multimodality treatment for curatively-treated gastroesophageal adenocarcinoma (GEA), prognosis remains dismal. The benefit of adding trastuzumab to chemotherapy for advanced Human Epidermal Growth Factor 2 (HER2) positive GEA has been established in the ToGA trial. However, it remains unclear if HER2 inhibition might also be beneficial in the curative setting. Therefore, we conducted a systematic review to investigate the role of HER2 inhibitors for the curative treatm...
#1Keiichiro Mori (Jikei University School of Medicine)H-Index: 8
#2Benjamin Pradere (Medical University of Vienna)H-Index: 14
Last. Karim Bensalah (University of Rennes)H-Index: 64
view all 0 authors...
BACKGROUND The programmed cell death ligand-1 (PD-L1)/programmed cell death-1 (PD-1) pathway is important in metastatic renal cell carcinoma (mRCC). However, some dissimilarities between anti-PD-1 and anti-PD-L1 inhibitors have emerged. We aimed to assess differences between anti-PD-1 and anti-PD-L1 combination immunotherapies as first-line treatments in mRCC patients. METHODS Multiple databases (PubMed, Web of Science, and Scopus) were searched for articles published until March 2021. Studies w...
#1Daniel L. Hertz (UM: University of Michigan)H-Index: 19
#2Daniel S. Childs (Mayo Clinic)H-Index: 2
Last. Charles L. Loprinzi (Mayo Clinic)H-Index: 110
view all 0 authors...
Recently updated American Society of Clinical Oncology (ASCO) guidelines for Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Survivors of Adult Cancers make a single recommendation to alter treatment by delaying, decreasing, or discontinuing dosing in patients who develop CIPN during neurotoxic chemotherapy treatment. Dosing guidelines have inconsistent recommendations for when (i.e., what CIPN severity) and how (i.e., delay, decrease, or discontinue) to alter n...
Abstract null null The development of cancer therapies using monoclonal antibodies has been successful during the last 30 years. Recently much progress was achieved with technologies involving bispecific and multi-specific antibodies. Bispecific antibodies (BsAbs) are antibodies that bind two distinct epitopes, and a large number of potential clinical applications of BsAbs have been described. Here we review mechanism of action, clinical development and future challenges of BsAbs which could be ...
#1Marie-France Savard (U of O: University of Ottawa)
#2Mark Clemons (U of O: University of Ottawa)H-Index: 61
Last. Carol Stober (Ottawa Hospital Research Institute)H-Index: 8
view all 0 authors...
Abstract null null Purpose null Radiation therapy (RT) and endocrine therapy (ET) are standard treatments for hormone receptor-positive (HR+) breast cancer after breast-conserving surgery (BCS). However, many older patients are at greater risk of treatment-related toxicities and non-cancer related death, and less likely to benefit from these standard treatments. A systematic review was performed evaluating outcomes of omitting RT or ET in older patients aged ≥50 treated with BCS for lower-risk b...
#2Lucia Carril-Ajuria (Institut Gustave Roussy)H-Index: 2
Last. Guillermo VelascoH-Index: 55
view all 0 authors...
Abstract null null Immune-checkpoint inhibitor-based therapy has revolutionized the natural history of metastatic renal cell carcinoma (mRCC) providing better survival outcomes, higher rates of complete responses (CR) and durable remissions. Along with these advances, new challenges have emerged. RECIST and new immune-response criteria may be equivocal identifying complete responses. How to define a durable response and what is the optimal treatment duration remains unclear. Furthermore, the rea...
Abstract null null Genetic alterations affecting RAS proteins are commonly found in human cancers. Roughly a fourth of melanoma patients carry activating NRAS mutations, rendering this malignancy particularly challenging to treat. Although the development of targeted as well as immunotherapies led to a substantial improvement in the overall survival of non-NRASmut melanoma patients (e.g. BRAFmut), patients with NRASmut melanomas have an overall poorer prognosis due to the high aggressiveness of ...
Top fields of study
Breast cancer